Your browser doesn't support javascript.
loading
Assessing the population relevance of endocrine-disrupting effects for nontarget vertebrates exposed to plant protection products.
Crane, Mark; Hallmark, Nina; Lagadic, Laurent; Ott, Katharina; Pickford, Dan; Preuss, Thomas; Thompson, Helen; Thorbek, Pernille; Weltje, Lennart; Wheeler, James R.
Afiliación
  • Crane M; AG-HERA, Faringdon, United Kingdom.
  • Hallmark N; Bayer SAS, Crop Science Division, Regulatory Toxicology, Sophia-Antipolis Cedex, France.
  • Lagadic L; Bayer AG, Crop Science Division, Environmental Safety, Monheim am Rhein, Germany.
  • Ott K; BASF SE, Crop Protection-Ecotoxicology, Limburgerhof, Germany.
  • Pickford D; Syngenta, Jealott's Hill International Research Station, Bracknell, United Kingdom.
  • Preuss T; Bayer AG, Crop Science Division, Environmental Safety, Monheim am Rhein, Germany.
  • Thompson H; Syngenta, Jealott's Hill International Research Station, Bracknell, United Kingdom.
  • Thorbek P; Syngenta, Jealott's Hill International Research Station, Bracknell, United Kingdom.
  • Weltje L; Present address: BASF SE, APD/EE, Limburgerhof, Germany.
  • Wheeler JR; BASF SE, Crop Protection-Ecotoxicology, Limburgerhof, Germany.
Integr Environ Assess Manag ; 15(2): 278-291, 2019 Mar.
Article en En | MEDLINE | ID: mdl-30520244
ABSTRACT
The European Commission intends to protect vertebrate wildlife populations by regulating plant protection product (PPP) active substances that have endocrine-disrupting properties with a hazard-based approach. In this paper we consider how the Commission's hazard-based regulation and accompanying guidance can be operationalized to ensure that a technically robust process is used to distinguish between substances with adverse population-level effects and those for which it can be demonstrated that adverse effects observed (typically in the laboratory) do not translate into adverse effects at the population level. Our approach is to use population models within the adverse outcome pathway framework to link the nonlinear relationship between adverse effects at the individual and population levels in the following way (1) use specific protection goals for focal wildlife populations within an ecosystem services framework; (2) model the effects of changes in population-related inputs on focal species populations with individual-based population models to determine thresholds between negligible and nonnegligible (i.e., adverse) population-level effects; (3) compare these thresholds with the relevant endpoints from laboratory toxicity tests to determine whether they are likely to be exceeded at hazard-based limits or the maximum tolerated dose/concentration from the experimental studies. If the population threshold is not exceeded, then the substance should not be classified as an endocrine disruptor with population-relevant adversity unless there are other lines of evidence within a weight-of-evidence approach to challenge this. We believe this approach is scientifically robust and still addresses the political and legal requirement for a hazard-based assessment. Integr Environ Assess Manag 2019;15278-291. © 2018 The Authors. Integrated Environmental Assessment and Management published by Wiley Periodicals, Inc. on behalf of Society of Environmental Toxicology & Chemistry (SETAC).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medición de Riesgo / Contaminantes Ambientales / Disruptores Endocrinos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Integr Environ Assess Manag Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medición de Riesgo / Contaminantes Ambientales / Disruptores Endocrinos Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Integr Environ Assess Manag Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido
...